Taylor, Graham S <br/><br/>
A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Oct 2014 
 - 5009-22 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-14-1122-T  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Cancer Vaccines--administration & dosage<br/>Combined Modality Therapy<br/>Epitopes, T-Lymphocyte--immunology<br/>Epstein-Barr Virus Infections--complications<br/>Epstein-Barr Virus Nuclear Antigens--genetics<br/>Female<br/>Herpesvirus 4, Human--genetics<br/>Humans<br/>Immunophenotyping<br/>Lymphocyte Count<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Neoplasms--diagnosis<br/>T-Cell Antigen Receptor Specificity<br/>T-Lymphocyte Subsets--immunology<br/>Treatment Outcome<br/>Vaccination<br/>Vaccinia virus--genetics<br/>Viral Load